SABS   $0.85  -4.92% Market Closed

SAB Biotherapeutics Inc
Last Events:

2023-07-30 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

2023-07-29 Trend pattern changed from канал to расширяющийся канал.

2023-07-29 Signal in MACD changed from bearish to bearish weakening. Oscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: signal line crossed the middle level.

2023-07-29 Signal in RSI changed from bearish weakening to bullish. RSI indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: exit from the overbought zone.

2023-07-29 Signal in EMA50 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-07-29 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-07-28 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-07-28 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.


Current temperature: 1.75
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 0.56
Target: 3.20
High with 49% probability: 1.62
Analyst Recommendations:
Number of estimates 3
Target Price Mean 3.20
Mean unverified/preliminary 3.20 / 3.20
Target Price Low / High 2.60 / 4.00
Median / STD DEV 3.00 / 0.72
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi ActivelyBuy Sell Sell
macd - - Sell
stoch - Sell -
ma20 ActivelyBuy Sell Sell
ma50 Sell - -
ma100 Sell Sell Sell
Candlestick PatternJuly 21, 2023 Bullish Harami - consists of an unusually large black body followed by a small white body contained within large black body. It is considered as a bullish pattern when preceded by a downtrend.
ISIN US78397T1034
ceo Mr. Samuel J. Reich
Website https://www.sabbiotherapeutics.com
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.